Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Selective sentinel lymphadenectomy for breast cancer.
Cox CE, Weinberg ES, Furman B, White LB, Patel J, Dickson DC, King J. Cox CE, et al. Among authors: patel j. Cancer Treat Res. 2005;127:77-104. doi: 10.1007/0-387-23604-x_4. Cancer Treat Res. 2005. PMID: 16209078 Review. No abstract available.
Stage T1A carcinoma of prostate.
Matzkin H, Patel JP, Altwein JE, Soloway MS. Matzkin H, et al. Among authors: patel jp. Urology. 1994 Jan;43(1):11-21. doi: 10.1016/s0090-4295(94)80254-8. Urology. 1994. PMID: 8284869 Review.
Correction: St. Jude Survivorship Portal: Sharing and Analyzing Large Clinical and Genomic Datasets from Pediatric Cancer Survivors.
Matt GY, Sioson E, Shelton K, Wang J, Lu C, Zaldivar Peraza A, Gangwani K, Paul R, Reilly C, Acić A, Liu Q, Sandor SR, McLeod C, Patel J, Wang F, Im C, Wang Z, Sapkota Y, Wilson CL, Bhakta N, Ness KK, Armstrong GT, Hudson MM, Robison LL, Zhang J, Yasui Y, Zhou X. Matt GY, et al. Among authors: patel j. Cancer Discov. 2024 Dec 2;14(12):2554. doi: 10.1158/2159-8290.CD-24-1432. Cancer Discov. 2024. PMID: 39618286 Free PMC article. No abstract available.
Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
Iyer SP, Sica RA, Ho PJ, Prica A, Zain J, Foss FM, Hu B, Beitinjaneh A, Weng WK, Kim YH, Khodadoust MS, Huen AO, Williams LM, Ma A, Huang E, Ganpule A, Nagar SD, Sripakdeevong P, Cullingford EL, Karnik S, Dequeant ML, Patel JN, He XS, Li Z, He QA, Mendonez JH, Keegan A, Horwitz SM. Iyer SP, et al. Among authors: patel jn. Lancet Oncol. 2024 Nov 28:S1470-2045(24)00508-4. doi: 10.1016/S1470-2045(24)00508-4. Online ahead of print. Lancet Oncol. 2024. PMID: 39617017
6,333 results